Biomea Fusion, Inc.

NASDAQ:BMEA

Biotechnology

Healthcare
$0.74 -2.50%

-$0.03 today

Market cap
$53.18M
Beta
-0.33
P/E (TTM)
-1.9
EPS (TTM)
-$0.62
52W Low $0.87High $2.99

Volume 3.50M

Average 1.52M

BMEA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Biomea Fusion, Inc.NASDAQ: BMEA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $12.42M (cash outflow) fell 57.6% year over year, ahead of the -65.1% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -8.9% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$49.78M (-19.4%) for the fiscal year ending Dec 2026, a step up from the -55.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.42M-369.2% QoQ
Last fiscal yearDec 2025
-$61.8M-55.4% YoY
LTMMar 2026
-$44.95M-65.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.6%-22.1%+35.5 pp
1 year-55.4%-19.4%+35.9 pp
3-year CAGR-8.9%-3.8%+5.2 pp
5-year CAGR-12.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(61.8M) USD
Year-over-year change
+55.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BMEA compares with its peers on the latest reported figures

  • BMEA's LTM Mar 2026 net income of $44.95M is the 8th largest of the 9 companies compared; the peer median is $96.07M.
  • Its year-over-year change of -65.1% is the 8th highest of 9, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of -8.9% compares with a peer median of +13.7%.
BMEA Competitors Peer median
Net Income for BMEA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M -37.4%+17.0%154.2%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108M +21.2%+44.8%—
IMUXImmunic, Inc.LTM Mar 2026$104.29M +8.2%-6.9%—
CBUSCibus, Inc.LTM Mar 2026$103.27M -65.4%+96.0%2409.4%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M -31.7%-6.3%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$86.3M +66.7%—2193.7%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$78.34M +28.7%+2.0%—
BMEABiomea Fusion, Inc.LTM Mar 2026$44.95M -65.1%-8.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$39.95M +162.9%+13.7%—
Peer median (excluding BMEA) $96.07M+14.7%+13.7%2193.7%

Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Depreciation & Amortization249K691K1.52M1.75M1.41M
Deferred Income Tax00000
Stock-Based Compensation6.23M10.34M14.13M19.09M9.52M
Change in Working Capital(1.57M)7.67M2.33M(5.15M)(3.7M)
Accounts Receivables00000
Inventory00000
Accounts Payables640K2.96M2.56M6.09M(9.7M)
Other Working Capital(2.21M)4.71M(232K)(11.24M)6M
Other Non-Cash Items1.22M715K2.69M2.84M(15.81M)
Operating Cash Flow(35.44M)(62.42M)(96.59M)(119.89M)(70.37M)
Capital Expenditures(3.17M)(1.03M)(3.37M)(362K)0
Acquisitions (Net)00000
Purchases of Investments(38.49M)0000
Sales of Investments8.31M28.37M1.15M00
Other Investing Activities00000
Investing Cash Flow(33.35M)27.34M(2.22M)(362K)0
Debt Repayment(36K)0000
Common Stock Issued153.22M0161.8M1.67M67.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.24M2M00
Financing Cash Flow153.19M1.24M163.8M1.67M67.9M
Effect of Forex Changes(351K)0000
Net Change in Cash84.04M(33.84M)64.99M(118.59M)(2.47M)
Free Cash Flow(38.61M)(63.45M)(99.96M)(120.26M)(70.37M)

Biomea Fusion, Inc.

NASDAQ:BMEA

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.